
|Articles|December 1, 2001
Policy changes offer steady AK coverage but diminished reimbursement
The destruction of benign, malignant, and premalignant lesions has beenand continues to be the main income stream
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Transformative Advances This Year and Beyond
5


















